Physician profile
Renanit E Barron
NPI 1760408215
$6,097.64
in general payments reported to CMS, 2019-2025
49 companies · $2,153 in 2025
The $2,153 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $149 · 2021: $518 · 2022: $741 · 2023: $682 · 2024: $1,306 · 2025: $2,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,134 · Education: $7.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,133.84 |
| Education | $7.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $899.44 | 2023-2025 | Evenity, Tavneos, Tepezza |
| Abbvie INC. | $607.81 | 2019-2025 | |
| Novo Nordisk INC | $591.55 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $414.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $278.51 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $228.46 | 2021-2023 | Tremfya |
| Sanofi-Aventis U.S. LLC | $222.63 | 2019-2024 | |
| Ascendis Pharma Endocrinology INC | $205.62 | 2023-2025 | Yorvipath |
| Corcept Therapeutics | $185.15 | 2023-2025 | Korlym |
| Ucb, INC. | $161.16 | 2021-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $152.83 | 2021-2024 | Benlysta |
| Beta Bionics, INC. | $149.41 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Astrazeneca Pharmaceuticals Lp | $148.49 | 2025 | Saphnelo |
| Abbott Laboratories | $137.87 | 2019-2025 | Freestyle Libre 3, Eterna |
| Mannkind Corporation | $118.36 | 2019-2023 | Afrezza |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renanit Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.